comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 02:29:58 - browse：1295

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The FDA weighs the risks of candy

WSS

Investment in vaccine development is lagging, report finds

FTC sues over Novant Health acquisition of two N.C. hospitals

Health Care Service Corp to buy Cigna Medicare Advantage plans

The pink breast cancer awareness ribbon needs a redesign

New clues to why women have higher risk of autoimmune disorders

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

explore

comprehensive

focus

Virginia high school admissions case could be legal follow

Wegovy leads to weight loss. Can it treat depression, too?

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Medicare proposal to cover medical devices draws a mixed reaction

Telehealth options flood the market as retailers push virtual care

Heart attack and stroke risk calculators need revising

Biogen walks away from Aduhelm, years after polarizing approval

Drug repurposing or repositioning? The language matters

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Wikipedia

Medicare Advantage insurers face 0.2% cut to 2025 payments

Cassava reveals details — and problems — with Alzheimer's study

How generative AI ratchets up security threats for health systems

Medtronic CEO on promising devices for diabetes, hypertension

Reconstructing family trees of blood cells may help predict disease

Emergency medicine has repudiated 'excited delirium.' Now what?

Wikipedia

explore

hotspot

focus